John W. Blankenship

1.9k total citations · 1 hit paper
22 papers, 1.5k citations indexed

About

John W. Blankenship is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, John W. Blankenship has authored 22 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in John W. Blankenship's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Chemical Synthesis and Analysis (3 papers). John W. Blankenship is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Chemical Synthesis and Analysis (3 papers). John W. Blankenship collaborates with scholars based in United States, Canada and Switzerland. John W. Blankenship's co-authors include Wayne J. Fairbrother, Kerry Zobel, Kurt Deshayes, Anna Fedorova, Eugene Varfolomeev, Domagoj Vucic, Linda O. Elliott, John A. Flygare, Parie Garg and Jasmin N. Dynek and has published in prestigious journals such as Cell, Journal of Molecular Biology and Biochemistry.

In The Last Decade

John W. Blankenship

21 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis

2007 1.0k citations Eugene Varfolomeev, John W. Blankenship et al. Cell profile →

Peers

Countries citing papers authored by John W. Blankenship

Since Specialization

Citations

This map shows the geographic impact of John W. Blankenship's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Blankenship with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Blankenship more than expected).

Fields of papers citing papers by John W. Blankenship

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Blankenship. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Blankenship. The network helps show where John W. Blankenship may publish in the future.

Co-authorship network of co-authors of John W. Blankenship

This figure shows the co-authorship network connecting the top 25 collaborators of John W. Blankenship. A scholar is included among the top collaborators of John W. Blankenship based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. Blankenship. John W. Blankenship is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clearance of plasma PCSK9 via the asialoglycoprotein receptor mediated by heterobifunctional ligands 2023 ·Cell chemical biology ·Jeffrey T. Bagdanoff, Thomas M. Smith, Martin Allan, Peter H. O’Donnell, (unknown), Elizabeth A. Moore, (unknown), Shuangxi Wang, Vanitha Subramanian, Bruno Tigani, David O. Nettleton, Lauren G. Monovich, Ian Lewis, (unknown), Brian Granda, John W. Blankenship, David Barnes‐Seeman, Kevin B. Clairmont	22
2	MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer 2016 ·Molecular Cancer Therapeutics ·Gabriela Hernández‐Hoyos, (unknown), (unknown), (unknown), (unknown), (unknown), Maria Dasovich, Hang Fang, Rebecca Gottschalk, (unknown), Robert E. Miller, (unknown), (unknown), Paul A. Algate, David Bienvenue, Catherine J. McMahan, (unknown), Jane A. Gross, John W. Blankenship	56
3	Abstract 4995: anti-ROR1 x anti-CD3 ADAPTIR™ molecule, ES425, redirects T-cell cytotoxicity and inhibits tumor growth in preclinical models of triple-negative breast cancer 2016 ·Cancer Research ·John W. Blankenship, Lynda Misher, (unknown), Nicole Zhang, Philip Tan, (unknown), (unknown), (unknown), Catherine J. McMahan, Robert E. Miller, (unknown), Hang Fang, (unknown), Maria Dasovich, David Bienvenue, (unknown), (unknown), (unknown), (unknown), Jane A. Gross	3
4	Internal motions prime cIAP1 for rapid activation 2014 ·Nature Structural & Molecular Biology ·Aaron H. Phillips, Allyn J. Schoeffler, Tsutomu Matsui, Thomas Weiß, John W. Blankenship, Kerry Zobel, Anthony M. Giannetti, Erin C. Dueber, Wayne J. Fairbrother	18
5	319 Anti-PSMA X Anti-CD3 Bispecific Antibody Efficiently Redirects T Cell Cytotoxicity in Castrate-resistant Prostate Cancer Models 2012 ·European Journal of Cancer ·(unknown), Gabriela Hernández‐Hoyos, (unknown), (unknown), (unknown), Suchitra Natarajan, Catherine J. McMahan, P A Algate, John W. Blankenship	1
6	Small-Molecule Ligands of GD2 Ganglioside, Designed from NMR Studies, Exhibit Induced-Fit Binding and Bioactivity 2010 ·Chemistry & Biology ·(unknown), Martin Gagnon, Tara Sprules, Michel Gilbert, Shafinaz F. Chowdhury, Karen Meerovitch, Karl A. Hansford, Enrico O. Purisima, John W. Blankenship, Nai‐Kong V. Cheung, Kalle Gehring, William D. Lubell, H. Uri Saragovi	10
7	Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2 2008 ·Biochemical Journal ·John W. Blankenship, Eugene Varfolomeev, Tatiana Goncharov, Anna Fedorova, Donald S. Kirkpatrick, Anita Izrael-Tomasevic, Lilian Phu, David Arnott, Mariam Aghajan, Kerry Zobel, J. Fernando Bazán, Wayne J. Fairbrother, Kurt Deshayes, Domagoj Vucic	93
8	Threading a peptide through a peptide: Protein loops, rotaxanes, and knots 2007 ·Protein Science ·John W. Blankenship, Philip E. Dawson	35
9	IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis breakdown → 2007 ·Cell ·Eugene Varfolomeev, John W. Blankenship, (unknown), Anna Fedorova, Nobuhiko Kayagaki, Parie Garg, Kerry Zobel, Jasmin N. Dynek, Linda O. Elliott, Heidi J.A. Wallweber, John A. Flygare, Wayne J. Fairbrother, Kurt Deshayes, Vishva M. Dixit, Domagoj Vucic	1013
10	Examination of structural characteristics of the potent oxytocin antagonists [dPen1,Pen6]-OT and [dPen1,Pen6, 5-tBuPro7]-OT by NMR, raman, CD spectroscopy and molecular modeling 2005 ·Journal of Peptide Science ·Laurent Bélec, John W. Blankenship, William D. Lubell	6
11	Thermodynamics of a Designed Protein Catenane 2003 ·Journal of Molecular Biology ·John W. Blankenship, Philip E. Dawson	41
12	Probing Backbone Hydrogen Bonds in the Hydrophobic Core of GCN4 2002 ·Biochemistry ·John W. Blankenship, (unknown), Philip E. Dawson	37
13	Replacement of the Axial Histidine Ligand with Imidazole in Cytochrome c Peroxidase. 1. Effects on Structure^, 2001 ·Biochemistry ·Judy Hirst, Sheri K. Wilcox, Pamela A. Williams, John W. Blankenship, Duncan E. McRee, David B. Goodin	29
14	Hybrid Operating Strategy and Energy Management for a Hybrid Electric Vehicle 2001 ·Dynamic Systems and Control ·K.E. Bailey, (unknown), Anthony M. Phillips, John W. Blankenship, S.R. Cikanek	1
15	Site-site communication in the EF-hand Ca2+-binding protein calbindin D9k. 2000 ·Nature Structural Biology ·(unknown), (unknown), John W. Blankenship, Mark Rance	71
16	Interstitial cystitis: The painful bladder syndrome 2000 ·PubMed ·(unknown), John W. Blankenship, Scott MacDiarmid	3
17	Rational Design of a Functional Metalloenzyme: Introduction of a Site for Manganese Binding and Oxidation into a Heme Peroxidase 1998 ·Biochemistry ·Sheri K. Wilcox, Christopher D. Putnam, Mallika Sastry, John W. Blankenship, Walter Chazin, Duncan E. McRee, David B. Goodin	40
18	Collagen metabolism and spicule formation in sea urchin micromeres 1984 ·Experimental Cell Research ·John W. Blankenship, Stephen C. Benson	46
19	Metabolism of N1-Acetylspermidine and N8-Acetylspermidine in Rats 1984 ·Experimental Biology and Medicine ·John W. Blankenship, (unknown)	11
20	Cytogenetic Studies of Normal and Cleft-Palate Epitheliums in Mice 1969 ·Journal of Dental Research ·Carlos E. Nasjleti, Herbert H. Spencer, John W. Blankenship, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact